Q1 2024 Orexo AB Earnings Call Transcript
Thank you very much, and my clock went a little earlier, so I will take a slow start here, but -- So welcome to the Orexo first quarter results. As our headline indicate, we think one of the main items for this quarter is -- this is the first real quarter where we can show that our guidance and our monitoring of our underlying profitability is actually correct. And we had some significant nonrecurring expenses during '23 and -- in the very beginning of '23 and 2022.
And now we are in the first quarter, a lot of these expenses have gone away. So we have seen the EBITDA improvement compared to last year with SEK57 million, which is very much in line with our guidance and that's a little better than I think both we and the market had expected. However, this quarter also had a little mix pack because our Zubsolv sales and I'll come back to that, was not fully meeting our expectations, but I believe there are some good explanations to that.
And on top of that, we have an R&D development where some have very good and others,
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
